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Abstract
Background: We have recently analyzed the profile of T-cell subtypes based on chemokine receptor expression in
blood from untreated early rheumatoid arthritis (ueRA) patients compared to healthy controls (HC). Here, we
compared the levels of the respective chemokines in blood plasma of ueRA patients with those of HC. We also
studied the association of chemokine levels with the proportions of circulating T-cell subsets and the clinical
disease activity.
Methods: Peripheral blood was obtained from 43 patients with ueRA satisfying the ACR 2010 criteria and who
had not received any disease-modifying anti-rheumatic drugs (DMARD) or prednisolone, and from 14 sex- and
age-matched HC. Proportions of T helper cells in blood, including Th0, Th1, Th2, Th17, Th1Th17, TFh, and regulatory
T cells, were defined by flow cytometry. Fifteen chemokines, including several CXCL and CCL chemokines related
to the T-cell subtypes as well as to other major immune cells, were measured in blood plasma using flow cytometry
bead-based immunoassay or ELISA. Clinical disease activity in patients was evaluated by assessing the following
parameters: Disease Activity Score in 28 joints (DAS28), Clinical Disease Activity Index (CDAI), swollen joint counts (SJC),
tender joint counts (TJC), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). The data were analyzed
using multivariate factor analyses followed by univariate analyses.
Results: Multivariate discriminant analysis showed that patients with ueRA were separated from HC based on the
blood plasma chemokine profile. The best discriminators were CXCL9, CXCL10, CXCL13, CCL4, and CCL22, which were
significantly higher in ueRA compared to HC in univariate analyses. Among the chemokines analyzed, only CXCL10
correlated with multiple disease activity measures, including DAS28-CRP, DAS28-ESR, CDAI, SJC in 66 joints, CRP,
and ESR.
Conclusions: High circulating levels of CXCL10 in the plasma of ueRA patients and the association with the clinical
disease activity suggests that CXCL10 may serve as a disease activity marker in early rheumatoid arthritis.
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Background
Rheumatoid arthritis (RA) is a chronic and systemic
inflammatory disease characterized by synovial inflam-
mation and progressive destruction of joint cartilage and
bones [1, 2]. The etiopathogenesis of RA is not fully
understood, but various leukocytes including T cells, B
cells, monocytes, neutrophils, eosinophils, dendritic cells
(DC), and natural killer (NK) cells, as well as soluble
factors such as cytokines and chemokines, are suggested
to be involved in disease pathogenesis [2–4]. It is
believed that early RA constitutes a ‘window of opportun-
ity’ when appropriate therapy may halt the irreversible
damage and prevent the switch from acute resolving
inflammation to chronic and persistent inflammation
[5, 6]. However, our current understanding of patho-
genic mechanisms in early and preclinical RA is even
less than that in established RA.
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In the current paradigm of the T-cell subsets, T helper
(Th)1 and Th17 cells are mainly described as contribut-
ing to RA pathogenesis [2, 3, 7]. However, it has been
shown that the profile of synovial fluid (SF) cytokines in
very early RA is different from that in established RA,
and has a Th2 and Th17 bias (i.e., displays elevated con-
centration of interleukin (IL)-2, IL-4, IL-13, IL-17, IL-15,
basic fibroblast growth factor, and epidermal growth
factor compared to established RA) [8]. It has also been
shown that untreated patients with very early RA
(disease duration less than 6 weeks) display increased
serum levels of cytokines related to Th17 polarization
and neutrophil recruitment and activation compared to
healthy controls (HC) [9]. Another study using T-cell
clones from synovial fluid found that IL-4 production
was predominant in early RA patients, whereas inter-
feron (IFN)γ production was predominant in established
RA patients [10]. These findings point to differences in
the profile of inflammatory mediators in early RA versus
established RA. Recently, we have performed a broad-
scale analysis of blood T-cell subtypes based on
chemokine receptor expression in patients with untreated
early rheumatoid arthritis (ueRA) compared to HC [11].
The analyzed T-cell subsets included well-defined Th1,
Th2, Th17, (T follicular helper (TFh), Th1Th17 and regu-
latory T cell (Treg) subsets, and also unconventional T-
cell subsets as such CXCR3+Th17, CXCR3+Th2, and
CCR4negCXCR3negCCR6+ (denoted CCR6+ only). The
above study from our group demonstrated that the
balance of T-helper subsets in the circulation of ueRA
patients is skewed towards Th2 and Th17 cells.
During synovial inflammation, leukocyte trafficking
to synovial tissue is a key pathogenic process in RA,
which is mediated by chemokines and chemokine
receptors [3, 12]. Published studies on the chemokine
levels in the circulation or in the synovium have not
sub-classified patients into early versus established
RA, or treated versus untreated groups. For example,
a study including patients with early RA investigated
chemokines in serum, but 41% of the patients were
treated with disease-modifying anti-rheumatic drugs
(DMARD) [13]. Similarly, in another cohort with
pre-patients and early RA patients in which blood
chemokines were investigated, 39% of the patients
were treated with prednisolone [14]. Treatment with
biological and non-biological DMARD in RA have
been shown to alter the chemokine levels in the blood
[15–18], suggesting a need to evaluate chemokines in a
pure group of DMARD-naive ueRA patients.
In our previous study in ueRA patients, T-helper cell
subsets could be defined based on a combination of four
chemokine receptors, i.e., CCR4, CCR6, CXCR3, and
CXCR5 in the CD4+ or CD4+CD45RAneg compartment
[11]. In this study we therefore questioned if any of the
chemokines that bind to the above chemokine receptors
are differentially present in the blood of ueRA patients
compared to HCs and how they relate to T-cell subsets
and clinical disease activity. We analyzed the following
15 chemokines (cells expressing corresponding chemo-
kine receptor shown in brackets): CXCL9, CXCL10, and
CXCL11 (Th1 and NK cells), CCL2, CCL3, CCL4, and
CCL5 (Th2, macrophages, NK cells), CCL17 and CCL22
(Th2 and Tregs), CCL20 (Th17, B cells, and dendritic
cells), CXCL13 (TFh and B cells), CCL11 (eosinophils
and basophils), and CXCL1, CXCL5, and CXCL8
(neutrophils). We also investigated how chemokine
levels were related to T-cell subset proportions and
clinical disease activity in ueRA. By the use of multivari-
ate analysis, we found that the ueRA patients were sepa-
rated from HCs based on their chemokine profile. We
also found that the circulating levels of CXCL9,
CXCL10, CXCL13, CCL4, and CCL22 were significantly
higher in ueRA compared to HCs. Among the discrimin-
ator chemokines, only CXCL10 correlated with clinical
disease activity.
Methods
Patients and healthy controls
The patient group comprised of 43 subjects who were
newly diagnosed with RA according to the ACR/EULAR
2010 criteria and who were all untreated (ueRA). The
inclusion criteria were as follows: ≥18 years old, ≥2
swollen joints (SJC 66) and ≥2 tender joints (TJC 68)
(based on 66/68 joint count, respectively), rheumatoid
factor (RF)-positive or anti-citrullinated protein/peptide
antibody (ACPA)-positive or C-reactive protein (CRP)
≥10 mg/L, at least moderate disease activity (>3.2) by
composite index Disease Activity Score in 28 joints
(DAS28-CRP), symptom duration <24 months (retro-
spective patient-reported symptoms), and no treatment
with any DMARD or prednisolone. Blood samples were
drawn from the DMARD- and prednisolone-naïve pa-
tients within 1–2 weeks after RA diagnosis. The patient
group was compared to a group of 14 age- and sex-
matched healthy control subjects (HC). Characteristics
of patients and HC are shown in Table 1. The median
age of the patient cohort (61 years, range 22–78 years)
and HC (62.5 years, range 35–72 years) was not signifi-
cantly different (P = 0.68). The patients were recruited at
the Rheumatology clinics at Sahlgrenska University
Hospital and at Skåne University Hospital, Sweden. The
study was approved by the regional ethics committee of
Gothenburg, Sweden, and all patients signed an informed
consent form.
Clinical evaluation
Evaluation of clinical disease activity in patients was
done by assessing the following parameters: swollen joint
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counts of 66 joints (SJC 66), tender joint counts of 68
joints (TJC 68), swollen joint counts in 28 joints status
(SJC 28), tender joint counts in 28 joints status (TJC 28),
CRP, erythrocyte sedimentation rate (ESR), Disease
Activity Score in 28 joints (DAS28) [19] and Clinical
Disease Activity Index (CDAI) [20, 21]. ACPA positivity was
determined by multiplexed anti-CCP test (BioPlex from
BioRad, Hercules, USA) and RF positivity was determined
by nephelometry (Beckman Coulter, Brea, USA). Patients
with ≥20 IU/ml anti-CCP antibodies or RF in serum were
considered ACPA- or RF-positive, respectively.
Chemokine analysis
Chemokine analysis was performed in blood plasma of
ueRA patients and HCs. The chemokines CCL2 (MCP-1),
CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES),
CCL17 (TARC), CCL20 (MIP-3α), CXCL1 (GROα),
CXCL5 (ENA-78), CXCL8 (IL-8), CXCL9 (MIG), CXCL10
(IP-10), and CXCL11 (I-TAC) were analyzed using flow
cytometry bead-based immunoassay (LEGENDplex™
Human Proinflammatory Chemokine Panel, BioLegend)
according to the manufacturer’s instructions, and samples
were acquired on a FACSVerse equipped with FACSuite
software (BD Bioscience, San Jose, USA), and analyzed
with FCAP Array software (Soft Flow, Pecs, Hungary).
CCL22 (MDC) and CXCL13 (BCL) were not available in
the above multiplexed assay, and therefore these chemo-
kines were analyzed using enzyme-linked immunosorbent
assay (ELISA; DuoSet, R&D Systems). CCL11 (Eotaxin)
was analyzed by the use of ELISA (DuoSet) since the
values obtained in the bead-based immunoassay above
were too high compared to previously published levels in
healthy controls.
Definition, analysis, and characterization of T-cell subsets
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from whole blood (for patients sampled within 1–
2 weeks after RA diagnosis) using Lymphoprep (Axis-
Shield, Oslo, Norway). For cell counts (true count; TC),
we used the BD TruCOUNT Absolute Counting Tubes
with the addition of CD45 PerCP and CD4 APC-H7
antibodies (BD Biosciences). T-cell subsets were defined
and analyzed using flow cytometry, and the phenotypes
of defined T-cell subsets were confirmed by lineage-
specifying transcription factor expression by quantitative
polymerase chain reaction (qPCR) and cytokine secre-
tion by Cytometric Bead Array as described in a previ-
ous study from our group [11]. In brief, the cell surfaces
of PBMCs were stained with fluorochrome conjugated
monoclonal antibodies against the following molecules:
CD4, CD45RA, CCR4, CCR6, CXCR3, CXCR5, CD127,
and CD25; to evaluate FOXP3+ and CTLA-4+ cells,
intracellular stainings were performed [11]. Stained sam-
ples were acquired using FACSCanto II equipped with
FACS Diva software. Flow cytometry data were analyzed
in FlowJo software (Tree Star, Ashland, USA). The
gating strategy to define different T-cell subsets is previ-
ously described in detail [11], and also presented in
Additional file 1 (Figure S1).
Statistical analysis
Multivariate factor analysis (SIMCA-P+ software; Umetrics,
Umeå, Sweden) was used to investigate the associations of
chemokines and T-cell subsets (x variables) with ueRA or
HC, to investigate the relationship between chemokines and
T-cell subsets (x variables) in ueRA patients, and to investi-
gate the association between chemokines (y variables) and
disease activity variables (x variables) in ueRA patients.
Orthogonal projection to latent structures discriminant
analysis (OPLS-DA) was implemented to examine whether
ueRA patients, compared with HC, could be discriminated
based on the various x variables (chemokines and/or T-cell
subsets) examined. The two-class discrimination OPLS-DA
model has one predictive component and one orthog-
onal component, and the default score scatter plot is
t[1] vs to[1] (as shown in Figs. 1a and 2a). The scatter plot
of t[1] vs to[1] is a window in the x space in which the
Table 1 Baseline characteristics of early diagnosed untreated




Female (n (%)) 30 (69.7) 9 (64.2)
Age (years) a,b,c 61 (22–78) 62.5 (35–72)
Symptom duration (months) a,b,d 6 (2–23) ND
CRP (mg/L) a,b 9.1 (0.3–152) ND
ESR (mm/hour) a,b 26 (5–108) ND
Swollen joint count of 66 a,b 11 (2–30) ND
Tender joint count of 68 a,b 14 (3–47) ND
Swollen joint count of 28 a,b 9 (2–22) ND
Tender joint count of 28 a,b 9 (0–27) ND
DAS28-CRP a,b 5.1 (2.7–8) ND
DAS28-ESR a,b 5.3 (2.6–8.4) ND
CDAI a,b 28.1 (11.8–62.1) ND
ACPA ≥20 IU/ml (n (%)) 34 (79) ND
RF ≥20 IU/ml (n (%)) 33 (77) ND
ACPA ≥20 IU/ml + RF ≥20 IU/ml (n (%)) 30 (70) ND
ACPA <20 IU/ml + RF <20 IU/ml (n (%)) 5 (12) ND
aMedian and bRange
cP = 0.68 (statistical analysis between ueRA and healthy controls, Mann–
Whitney U test)
dRetrospective patient-reported pain in the joints before RA diagnosis
ACPA anti-citrullinated protein/peptide antibodies, CDAI Clinical Disease
Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score 28, ESR
erythrocyte sedimentation rate, ND not determined, RF rheumatoid factor,
ueRA untreated early rheumatoid arthritis
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Fig. 1 Differences in the levels of blood chemokines between untreated early rheumatoid arthritis patients and healthy controls. Multivariate
factor analysis was performed to investigate differences in the blood chemokine levels between the patients with untreated early rheumatoid
arthritis (ueRA; n = 43) and healthy controls (HC; n = 14). a Orthogonal projection to latent structures discriminant analysis (OPLS-DA) score scatter
plot showing the separation of ueRA and HC based on differences in chemokine levels. b OPLS-DA column loading plot depicting the association
between ueRA or HC (y variables) and the levels of chemokines (x variables). x variables represented by bars pointing in the same direction as
ueRA are positively associated, whereas variables with bars pointing in the opposite direction are inversely related to ueRA. R2Y indicates how
well the variation of y is explained, whereas Q2 indicates how well y can be predicted. c Univariate comparisons of the levels of CXCL9, CXCL10,
CCL22, CXCL13, CCL4, and CCL3 are shown between ueRA and HC. Horizontal bars indicate median. *P ≤ 0.05, **P≤ 0.01, ****P ≤ 0.0001, by two-
tailed Mann–Whitney U test
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Fig. 2 Differences in a combined blood chemokine/T-cell subset profile between untreated early rheumatoid arthritis patients and healthy
controls, and the association of chemokines and T-cell subsets. Multivariate factor analysis was performed to investigate differences in combined
blood chemokine levels and proportions of T-cell subset profiles between the patients with untreated early rheumatoid arthritis (ueRA; n = 43) and
healthy controls (HC; n = 14). a Orthogonal projection to latent structures discriminant analysis (OPLS-DA) score scatter plot showing the separation of
ueRA and HC based on differences in the combined blood chemokine/T-cell subset profile. b OPLS-DA column loading plot depicting the association
between ueRA or HC (y variables) and the levels of chemokines and T-cell subset proportions (x variables). x variables represented by bars pointing in
the same direction as ueRA are positively associated, whereas variables with bars pointing in the opposite direction are inversely related to ueRA.
c Principal component analysis (PCA) plot of the first two principal components (p2 vs p1) depicting the association and clustering among the
chemokines and T-cell subsets in the patients with ueRA. Subsets located close to each other on the same side of an axis depict positive association,
while subsets located far on the opposite side of an axis or located far diagonally depict negative association
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separation of the two classes of observations occurs in the
horizontal t[1] direction, and the vertical to[1] direction
depicts the within-class variability of the separation in
x-space. Principal component analysis (PCA) was per-
formed to examine how chemokines and the proportions
of T-cell subsets associate with each other in ueRA patients.
OPLS was implemented to find associations between
chemokines (y variables) and clinical disease activity mea-
sures (x variables) in linear multivariate models. Log trans-
formation was used to normalize data and further scaled to
unit variance in the SIMCA software by dividing each vari-
able by 1/standard deviation (SD), so that all the variables
were given equal weight regardless of their absolute value.
The scale presented on the axes of the PCA and OPLS
plots is a dimensionless scale, and the loading vector is nor-
malized to length one. The quality of the OPLS models was
assessed based on the parameters R2 (i.e., how well the
variation of the variables is explained by the model) and Q2
(i.e., how well a variable can be predicted by the model).
Univariate analyses were performed using two-tailed
Mann–Whitney U test and two-tailed Spearman rank cor-
relation test (GraphPad Prism Software, La Jolla, USA) as
described in the figure legends. The strength of correlation
was determined based on Spearman correlation coefficient
(r) values (r = 0.2–0.39, weak correlation; r= 0.4–0.59, mod-
erate correlation; r = 0.6–0.79, strong correlation; r >0.8,
very strong correlation). A P value ≤ 0.05 was regarded as
being statistically significant.
Results
Chemokine levels in blood are higher in ueRA patients
than in healthy controls
First, we asked whether there were any differences in the
levels of chemokines between ueRA patients and HCs.
Based on the chemokines assessed, OPLS-DA demon-
strated a separation between ueRA patients and HCs
(Fig. 1a). The majority of patients with ueRA appeared in
the two left quadrants, whereas all HCs appeared in the
two right quadrants. The chemokines that displayed the
strongest association (positive or negative) with ueRA
patients are identified in the OPLS-DA column plot in
Fig. 1b. ueRA was positively associated with higher levels of
most of the chemokines analyzed, except for eotaxin,
CXCL5, and CCL5 (Fig. 1b). The multivariate associations
were corroborated by univariate analyses, which demon-
strated that the CXCL9, CXCL10, CCL22, CXCL13, and
CCL4 levels were significantly higher in ueRA compared to
HCs (Fig. 1c). These results show that patients with ueRA
display higher levels of several blood chemokines compared
to HCs. In particular, levels of chemokines related to Th1
(CXCL9, CXCL10), Th2 (CCL22), T follicular helper and B
cells (CXCL13), and macrophages (CCL4) were higher in
ueRA compared to HCs.
A combined chemokine/T-cell subset profile increases the
separation between ueRA and HCs compared to the
chemokine profile or T-cell subset profile alone
We have previously demonstrated that the proportion of
various T-helper and T regulatory cell subsets in blood
can be used to separate ueRA from HCs [11]. Here, we
investigated how chemokines and T-cell subset propor-
tions together affect the separation between ueRA and
HCs. When compared to the chemokine profile alone
(Q2 = 0.29) (Fig. 1a) or the T-cell subset profile alone
(Q2 = 0.34; Additional file 1: Figure S2), the combined
chemokine and T-cell subset profile led to a stronger
separation between ueRA patients and HCs as demon-
strated by the increased predictability of the latter
OPLS-DA model (Q2 = 0.42) (Fig. 2a).
The OPLS-DA column plot in Fig. 2b displays the as-
sociation (positive or negative) of chemokines and T-cell
subsets with ueRA patients or HCs. As clearly demon-
strated, most of the chemokines were elevated among
the ueRA patients along with increased proportions of
CTLA-4+CD4+ T cells and Th2 cells. On the contrary,
none of the chemokines were higher among HC, while
the absolute number of CD4+CD45RAneg T cells
(memory/mature T cells) per ml of blood, as well as the
proportions of CCR6+ only and Th1Th17 subsets, were
higher in the HC group. In the combined OPLS-DA
analysis, CXCL10 among chemokines and Th2 cells
among T helper subsets in blood were most strongly
associated with ueRA (Fig. 2b).
In order to evaluate how chemokines and the corre-
sponding T-cell subsets associate with each other in
ueRA, a PCA analysis was performed including chemo-
kines and selected T-cell subsets based on results from
Fig. 2b. As shown in Fig. 2c, none of the chemokines
clustered together with the corresponding T-cell subset.
Instead, most chemokines were projected far from the
relevant T-cell subsets. For example, CXCL9, CXCL10,
and CXCL11 were projected on the opposite side of the
x axis from Th1 and Th1Th17 cells. Also, CCL20 was
located on the opposite side of the axis or diagonally
from Th17, CCR6+ only, and Th1Th17 subsets. Finally,
CCL2, CCL3, and CCL4 were located on the opposite
side of the axis or diagonally from Th2 cells. However,
no statistically significant inverse correlations were ob-
served between chemokine levels and the corresponding
T-cell subset proportions.
Overall, these results demonstrate that a combined profile
of chemokines and T-cell subsets led to stronger separation
between ueRA and HC compared to chemokine or T-cell
subset profiles alone. However, although the levels of some
chemokines and the proportions of the corresponding T-cell
subsets were elevated among ueRA patients, they were not
positively associated. Instead, they displayed a negative asso-
ciation pattern in multivariate PCA analysis.
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Only the levels of CXCL10 correlate with clinical disease
activity
We next investigated whether the chemokine levels in
plasma were associated with clinical disease activity in
ueRA patients. OPLS analysis showed that, among the
chemokines that were positively associated with ueRA
(Fig. 1b), CXCL10 resulted in the strongest predictive
OPLS model with clinical measures (Fig. 3a). In fact,
ba
c d
Fig. 3 Association of Th1 chemokines with clinical disease activity in ueRA. Orthogonal projection to latent structures (OPLS) column loading plot
depicting the association between CXCL10 (a), CXCL9 (c) or CXCL11 (d) (y variables) and clinical disease activity measures, age, and symptom
duration (x variables) in the patients with ueRA (n = 43). x variables represented by bars pointing in the same direction as the chemokine are
positively associated, whereas variables with bars pointing in the opposite direction are inversely related to the respective chemokine. A negative
Q2 value in (c) and (d) indicate that these OPLS models are not predictive. b The correlations of CXCL10 with clinical disease activity measures in
ueRA patients (Spearman rank correlation test; r). *P ≤ 0.05, **P ≤ 0.01. CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease
Activity Score in 28 joints, ESR erythrocyte sedimentation rate, SJC swollen joint counts, TJC tender joint counts
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high levels of CXCL10 were found to be positively asso-
ciated with all clinical disease activity measures (Fig. 3a).
In univariate analyses, CXCL10 levels significantly corre-
lated with DAS28-ESR, DAS28-CRP, CDAI, SJC 66, CRP,
and ESR (Fig. 3b), and a trend towards positive correl-
ation was seen with SJC28 (r = 0.27, P = 0.08). The levels
of CXCL10 associated negatively with symptom duration
in multivariate analysis (Fig. 3a), which was corroborated
by univariate correlation analysis (Fig. 3b).
Although CXCL9 and CXCL11, like CXCL10, are
ligands to CXCR3, CXCL9 levels were unrelated to
clinical disease activity (except for ESR) (Fig. 3c) and the
levels of CXCL11 displayed a trend towards negative
correlation with tender joint counts (Fig. 3d). Addition-
ally, levels of the Th17-related chemokine CCL20 dis-
played a positive association pattern to clinical disease
activity (Additional file 1: Figure S5), while levels of the
eosinophil-related chemokine eotaxin were negatively
related to clinical disease activity, although none of these
associations were significant in univariate correlation
analyses (Additional file 1: Figure S4).
Next, we evaluated sex-based differences in the levels
of chemokines in HC and ueRA patients. Although some
of the chemokines in HC displayed a pattern of positive
association with female sex in multivariate analysis, no
significant difference in univariate analyses was found
for chemokine levels between females and males in HC
(Additional file 1: Figure S3). In ueRA patients, the levels
of eotaxin associated negatively with female sex in multi-
variate analysis and female patients had significantly
lower levels of eotaxin compared to male patients
(Additional file 1: Figure S3) and HC females (P = 0.02).
No significant difference was found for the levels of
other chemokines between female and male patients.
Sex-based differences were also observed for the associ-
ation of eotaxin levels with the clinical disease activity.
In female patients, eotaxin displayed a negative associ-
ation with clinical disease measures in multivariate
analysis and correlated negatively with DAS28-ESR,
SJC66, CRP, and ESR (Additional file 1: Figure S4). In
contrast, in male patients eotaxin displayed a pattern of
positive association with clinical disease measures in
multivariate analysis; however, no significant correlation
could be seen in univariate analyses (Additional file 1:
Figure S4). Furthermore, CCL20 correlated positively
with DAS28-ESR, CRP, and ESR in female patients but
not in male patients (Additional file 1: Figure S5).
Sex-based differences were not observed for other
chemokines and their associations with clinical disease
activity (data not shown).
We also examined whether there were any differences
in the chemokine levels between ACPA+ and ACPAneg
ueRA patients, or between RF+ and RFneg ueRA patients,
or between seropositive (ACPA+ and/or RF+) ueRA and
seronegative (ACPAneg and RFneg) ueRA patients. How-
ever, we did not find any predictive OPLS-DA model in
which chemokine levels could be associated with the
above-stated ueRA subgroups (Additional file 1: Figure
S6). In univariate comparisons, only the levels of CCL4
were significantly higher in ACPA+ ueRA patients com-
pared to ACPAneg ueRA patients, and only the levels of
CCL17 were significantly higher in RF+ ueRA patients
compared to RFneg ueRA patients. The levels of other
chemokines did not differ between the above ueRA sub-
groups. Thus, the presence of RF or ACPA in the serum
did not seem to interfere with the measurement of the
chemokines in our study.
Since CXCL10 correlated with clinical disease activity
(Fig. 3a and b), OPLS and correlation analyses were per-
formed to investigate the association of CXCL10 with
other chemokines (Fig. 4). CXCL10 displayed a strong
correlation with CXCL11 and moderate correlations
both with CCL2 and CXCL9 (Fig. 4). CXCL10 also dis-
played weak correlations with CCL3 (r = 0.35, P = 0.02),
CXCL8 (r = 0.32, P = 0.03), and CCL20 (r = 0.33, P =
0.02) (Fig. 4). Taken together, although the levels of
CXCL10 (a Th1-related chemokine) correlated with sev-
eral of the other chemokines assessed, only the levels of
CXCL10 correlated with multiple clinical disease activity
measures in ueRA patients.
Discussion
Chemokines and chemokine receptors are involved in
leukocyte migration and inflammatory processes, and
are therefore suggested to be involved in RA pathogen-
esis. Indeed, in this study we found that the patients
with ueRA were separated from HC in multivariate dis-
criminant analysis based on the blood chemokine profile.
A combined profile of chemokines and T-cell subsets led
to stronger separation between ueRA and HC compared
to chemokine or T-cell subset profiles alone. The levels
of chemokines related to Th1 (CXCL9, CXCL10), Th2
(CCL22), T follicular helper and B cells (CXCL13), and
macrophages (CCL4) were significantly higher in ueRA
compared to HC, pointing to the role of these chemo-
kines and immune cells in early RA pathogenesis.
Among the discriminator chemokines, only the levels of
CXCL10 correlated with several clinical disease activity
parameters, including DAS28-CRP, DAS28-ESR, CDAI,
SJC in 66 joints, CRP, and ESR.
In line with our results, previous studies have reported
higher levels of CXCL10 in serum or plasma in patients
with both established RA [16] and early RA [13, 14]
compared to healthy controls. However, a significant
proportion of these patients were treated with DMARD
when chemokine levels were assessed. Similarly, higher
serum levels of CCL22 in patients with RA compared to
healthy controls have been reported previously; however,
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in that study, the majority of the patients were treated
with DMARD and there was no information concerning
the disease duration [22]. Various treatments have been
shown to affect the levels of chemokines in the circula-
tion [15–18], which suggests that evaluation of chemo-
kines in untreated patients might be advantageous.
Among the evaluated chemokines, only the plasma
levels of CXCL10 correlated with the clinical disease ac-
tivity in our cohort. In a previous study in established
RA, a correlation between CXCL10 and DAS28-CRP has
been seen, but no correlation with other clinical disease
activity measures such as swollen joint counts, CRP, and
ESR was observed [15]. Another study in established RA
did not observe any correlation between CXCL10 and
clinical disease activity measures [18]. Thus, ours is the
first study that defines CXCL10 as a disease activity
marker in early RA by demonstrating correlation be-
tween CXCL10 and multiple clinical disease activity
measures. The reduction in CXCL10 with symptom dur-
ation and correlations with multiple clinical disease
activity measures in early RA but not in established RA
suggests that CXCL10 plays a more critical role in the
early stages of the disease, and can function as a disease
activity marker in early RA.
CXCL10 (traditionally known as IFNγ-inducible 10-kd
protein or IP-10) can be secreted by several cell types
such as endothelial cells, fibroblasts, monocytes, neutro-
phils, dendritic cells, mesenchymal cells, keratinocytes,
astrocytes, and so forth [23–25]. CXCL10 can be
induced in response to IFNγ, IFN-α/β, IL-1β or tumor
necrosis factor (TNF) [26, 27]. Interestingly, the type I
interferon (IFN) signature has been demonstrated as a
biomarker of preclinical RA [28], and granulocytes are
shown to be a major contributor of this signature in
early arthritis [29]. Since IFN-α is a potent inducer of
CXCL10 [26], high levels of CXCL10 in early RA,
despite lower proportions of Th1 cells, may suggest that
type I IFN-dependent immune mechanisms could be im-
portant in preclinical and early RA. Moreover, the role
of Th17 cytokines is well established in neutrophil
a b
Fig. 4 Association of CXCL10 with other chemokines in untreated early rheumatoid arthritis patients. a Orthogonal projection to latent structures
(OPLS) column loading plot depicting the association between the levels of CXCL10 (y variables) and other chemokines (x variables) in patients
with ueRA (n = 43). x variables represented by bars pointing in the same direction as CXCL10 are positively associated, whereas variables with bars
pointing in the opposite direction are inversely related to CXCL10. b Correlation analyses between the levels of CXCL10 and other chemokines in
ueRA patients (Spearman rank correlation test; r). *P ≤ 0.05, *** P ≤ 0.001, **** P ≤ 0.0001
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activation and, according to recent models, Th2 and
Th17 pathways may amplify each other in certain condi-
tions [30]. Thus, the dominance of Th2 and Th17 milieu
may induce a granulocyte-mediated type I IFN response,
which may further induce downstream secretion of
CXCL10 and other chemokines contributing to early RA
pathogenesis.
CXCL10 can potentially regulate inflammation at sev-
eral levels, contributing to RA pathogenesis and disease
activity. CXCL10 and CXCR3 play crucial roles in
leukocyte homing to inflamed tissue and also in perpetu-
ation of inflammation and tissue damage [25]. In par-
ticular, CXCL10 promotes directional migration of
activated T cells, monocytes, and NK cells, induces in-
tegrin activation, and promotes T-cell adhesion to
endothelial cells [31, 32]. It can therefore coordinate re-
cruitment of various immune cells to the site of inflam-
mation. CXCL10 can also induce RANKL expression in
RA synoviocytes and CD4+ T cells [33], which may in-
duce bone resorption. It has been shown that stimula-
tion of fibroblast-like synoviocytes (FLS) with CXCL10,
CXCL9, and CCL2 enhances the proliferation of these
cells, which may lead to synovial hyperplasia [34]. Che-
mokines such as CXCL10, CXCL9, CCL5, CCL4, and
CCL2 can also stimulate FLS and chondrocytes to re-
lease inflammatory mediators including cytokines,
matrix metalloproteinases (MMPs), and other enzymes,
leading to degradation of the extracellular matrix and
cartilage [34–36]. Higher levels of CXCL10 and other
chemokines have indeed been detected both in synovial
fluid and synovial tissue of RA patients compared to
osteoarthritis patients [37, 38]. In patients with estab-
lished RA, a chemokine gradient with higher levels in
synovial fluid compared to blood has been reported for
CXCL10, CXCL9, CCL2, CCL3, CCL4, and CXCL8 [38].
Among these, differences in the levels of chemokines
were most dramatic for CXCL10 and CXCL8 (>10 times
higher concentration in RF synovial fluid compared to
RA serum for both chemokines) [38]. The relative levels
of chemokines between synovial and peripheral blood
compartments in early RA and how a chemokine gradi-
ent affects the selective recruitment of immune cell
subtypes in the joints of patients with early RA has not
been established.
We here show that the levels of CXCL10 levels corre-
lated strongly with those of CXCL11 and moderately
with CCL2 and CXCL9. However, only CXCL10 levels
correlated with clinical disease. This suggests that the
inflammation and disease severity in patients are directly
associated with the levels of CXCL10 but not with the
other CXCR3 ligands or chemokines. Supporting this
notion, a recent genetic association study based on
single nucleotide polymorphisms (SNPs) showed that
the CXCL10 GG genotype was an independent factor
associated with increased probability of extra-articular
manifestation development, while CXCL9 genotypes did
not display such an association [39]. In a study with syn-
ovial fibroblast cell lines from RA patients, significant
CXCL9 and CXCL10 secretion, but not CXCL11, could
be observed upon IFNγ stimulation, and only CXCL10
secretion, but not CXCL9 and CXCL11, was found upon
TNF or IL-1β stimulation [27]. However, when these
cells were stimulated with a combination of IFNγ and
TNF, significant secretion of all three chemokines
(CXCR3 ligands) was observed [27]. Thus, despite differ-
ential regulation of CXCL10 and other chemokines in
chronic inflammation, association among several chemo-
kines can be seen due to synovial hyperplasia and para-
crine activity/positive feedback loop among various
cytokines and chemokines.
It has been reported previously that the serum levels
of CXCL13 can act as a disease activity marker in early
RA [40, 41]. However, we did not observe any significant
correlations between CXCL13 and clinical disease activ-
ity measures in our cohort. The reasons for these differ-
ent results are unclear, but could be due to differences
in the percentages of ACPA+ and RF+ patients which
varied between our cohort and patient cohorts in previ-
ous studies. The patient cohort in the present study had
79% ACPA+ and 77% RF+ patients, while the study by
Bugatti et al. [41] had 49% ACPA+ and 57% RF+ patients,
and the study by Greisen et al. [40] had 63% ACPA+ and
71% RF+ patients. However, the levels of CXCL13 were
not significantly different between ACPA+ and ACPAneg
or RF+ and RFneg subgroups in our patient cohort.
Lower levels of eotaxin were found in female patients
compared to male patients and HC females in our study
cohort. Interestingly, eotaxin associated negatively with
clinical disease activity in female patients while it dis-
played a positive association pattern in male patients.
High serum levels of eotaxin have been shown to associ-
ate with less radiographic progression in an early
rheumatoid arthritis patient cohort which had 77.4%
female patients [42]. Based on our results, it would be
interesting to evaluate sex-based differences in immune
cells and soluble inflammatory mediators in larger
cohorts of patients.
A negative association pattern was seen between che-
mokines and the corresponding T-cell subsets in the
present study, which could have several explanations.
Chemokine-mediated apoptosis of T cells could be one
reason, as it has been shown that chemokines are able to
induce apoptosis in T cells depending on the co-
stimulating signals and the balance of downstream
signaling pathways [43, 44]. Alternatively, binding of
chemokines to the chemokine receptor-expressing cells
may lead to lower concentrations of chemokine protein
in the blood. Another possibility is the migration of T cells
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to target organs such as joints, but this should depend
more on the chemokine gradient between organ tissue
and blood and not on the absolute plasma levels of
chemokines.
Targeting of chemokines and chemokine receptors have
given favorable results in preclinical studies performed in
animal models of arthritis [4]. However, human clinical
trials targeting CCR2, CCR5, CCL2, and CXCL8 by small
molecules or monoclonal antibodies have failed to demon-
strate clinical efficacy in RA (reviewed in [4]). In contrast,
one publication of a phase II clinical trial using anti-
CXCL10 monoclonal antibody (MDX-1100) in established
RA patients who had responded inadequately to metho-
trexate (MTX) treatment showed that the response rate
was significantly higher in MDX-1100-treated patients at
week 12 according to the American College of Rheuma-
tology 20% criteria for improvement compared to the
placebo group [45].
Conclusions
Results from our study support a critical role of CXCL10
in the inflammatory cascade. The correlation of CXCL10
with clinical disease activity and with other chemokines
in ueRA patients suggests that CXCL10 plays a central
role in early RA inflammation and may serve as a dis-
ease activity marker in early RA.
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